Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.7205 +0.0047 (+0.66%)

Delayed Quote Updated: 9:44 AM EDT, Oct 2, 2026 Add to My Watchlist

Price and Volume

Volume	21,459
Open	0.7400
Bid (Size)	0.7133 (400)
Ask (Size)	0.7277 (300)
Prev. Close	0.7158
Today's Range	0.7133 - 0.7400
52wk Range	0.7093 - 480.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

September 23, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio

September 17, 2026

VANCOUVER, BC September 17, 2026 - TheNewswire— StickIt Technologies Inc. (CSE: STKT) (the "Company" or "StickIt"), a developer and patent holder of proprietary cannabinoid and plant extract delivery...

Via TheNewswire.com

Performance

YTD	-96.4%	-96.4%
1 Month	-60.6%	-60.6%
3 Month	-69.5%	-69.5%
6 Month	-93.3%	-93.3%
1 Year	-99.8%	-99.8%

More News

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.

September 17, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

September 11, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Unusual volume stocks in Tuesday's session ↗

September 08, 2026

Via Chartmill

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

September 08, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Which stocks are experiencing notable movement on Friday? ↗

September 04, 2026

Via Chartmill

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

September 04, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

September 01, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

August 24, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

August 13, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery

August 11, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study

August 06, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

What's going on in today's pre-market session ↗

August 03, 2026

Via Chartmill

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

August 03, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial

July 30, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

July 28, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market

July 20, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction

July 17, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI

July 16, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial

July 13, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

July 10, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

July 07, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength

June 29, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

June 22, 2026

From Clearmind Medicine Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Clearmind Medicine Inc. - Common Shares publicly traded?

Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.

What exchange does Clearmind Medicine Inc. - Common Shares trade on?

Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?

The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market

What is the current price of Clearmind Medicine Inc. - Common Shares?

The current price of Clearmind Medicine Inc. - Common Shares is 0.7205

When was Clearmind Medicine Inc. - Common Shares last traded?

The last trade of Clearmind Medicine Inc. - Common Shares was at 10/02/26 09:44 AM ET